This protocol is presented as a gift to humanity, born from a deep respect for the courage of patients and the scientific community dedication. We move forward , recognizing that every historical step in medicine was taken with the intent to progress. Our objective is to bridge the gap between historical administrative mandates and modern biochemical reality to achieve true biological harmony. The 2026 identification of the SLC7A1 and SLC7A2 proteins on the luminal surface of the brain’s vasculature confirms the critical importance of the blood-brain barrier’s metabolic integrity. While these transporters are currently viewed as vehicles for drug delivery, this work identifies them as the fundamental regulators of the Arginine-Flux. By analyzing the kinetic shifts initiated in 1874, we can now address the root cause of the metabolic imbalance identified as Alzheimer’s disease. The Alzheimer Protocol II is an invitation to transition from managed decay to universal vitality. By understanding the stoichiometric relationship between the CAT-1 transporter and the Arginine-Flux, we offer a technical resolution for neurodegeneration. We invite scientists and healers to join this effort in restoring the metabolic sovereignty of the human brain, ensuring that every individual can reach their full, productive potential. In the spirit of scientific truth and human unity, we begin.
Alejandro Armando CAPARÓ (Fri,) studied this question.